The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).
 
Stephen James Luen
No Relationships to Disclose
 
Roberto Salgado
Travel, Accommodations, Expenses - Roche; Roche
 
Maria Vittoria Dieci
Travel, Accommodations, Expenses - Celgene; Genomic Health
 
Andrea Vingiani
No Relationships to Disclose
 
Giuseppe Curigliano
Consulting or Advisory Role - Pfizer; Roche/Genentech
Speakers' Bureau - Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Rebekah Hubbard
No Relationships to Disclose
 
Carlos Castaneda Altamirano
No Relationships to Disclose
 
Joselyn Sanchez
No Relationships to Disclose
 
Timothy D'Alfonso
No Relationships to Disclose
 
Esther Cheng
No Relationships to Disclose
 
Miluska Castillo Garcia
No Relationships to Disclose
 
Sylvia Adams
Research Funding - Amgen; Genentech; Merck
 
Fahad Ahmed
No Relationships to Disclose
 
David L. Rimm
Stock and Other Ownership Interests - Pixel Gear
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Cell Signaling Technology; Genentech
Consulting or Advisory Role - Agendia; AstraZeneca; Bethyl Laboratories; Biocept; Bristol-Myers Squibb; Clearsight; Five Prime Therapeutics; Genoptix; Merck; Optra SCAN; Perkin Elmer; Ultivue
Research Funding - AstraZeneca/MedImmune (Inst); Cepheid; Gilead Sciences; NextCure (Inst); OncoPlex Diagnostics; Perkin Elmer; Pierre Fabre (Inst)
Patents, Royalties, Other Intellectual Property - Quantitative Immunofluorescence (AQUA) (Inst); Rarecyte Circulating tumor cells
Travel, Accommodations, Expenses - Genentech; NextCure; Ventana Medical Systems
 
Sandra Demaria
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; EMD Serono; Lytix Biopharma
Research Funding - Lytix Biopharma (Inst)
 
William Fraser Symmans
Stock and Other Ownership Interests - Delphi Diagnostics; ISIS Pharmaceuticals; Nuvera Biosciences
Consulting or Advisory Role - Roche/Genentech
Patents, Royalties, Other Intellectual Property - Intellectual property
Travel, Accommodations, Expenses - Luminex
 
Stefan Michiels
Consulting or Advisory Role - Genticel; Hexal; IDDI; Johnson & Johnson; Mabxience; QuintilesIMS; Roche; Steba Biotech
Patents, Royalties, Other Intellectual Property - Patent pending EP16? 305 838.1.
 
Sherene Loi
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - PI3K pathway gene signature granted by the European and US patent offices (Inst)